Discovery of Essential Genes as Possible Targets for Prostate Cancer Drug Development

Area of Science:

• Oncology
• Bioinformatics
• Computational Biology

Background:

• Prostate cancer (PCa) remains a significant cause of male mortality globally.
• Despite recent advances, novel therapeutic strategies for advanced PCa are still needed.
• Identifying new therapeutic targets and repurposing existing drugs can improve PCa treatment.

Purpose of the Study:

• To develop an integrated bioinformatics pipeline for identifying potential therapeutic targets and repurposed drugs for prostate cancer.
• To identify novel biomarker-drug pairings for PCa detection and therapy.
• To advance treatment options for advanced prostate cancer.

Main Methods:

• Integrated bioinformatics analysis of RNA-seq datasets to identify common differentially expressed genes (cDEGs).
• Protein-protein interaction (PPI) network analysis to identify 15 hub genes (HubGs).
• Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, drug-target docking, and molecular dynamics (MD) simulations.

Main Results:

• Identified 458 cDEGs and 15 HubGs critical in PCa.
• Lower expression of five HubGs (BIRC5, CDCA5, CENPF, NUSAP1, TK1) correlated with better patient survival, suggesting biomarker potential.
• Top 10 drug candidates were identified, with three complexes (BIRC5-adapalene, BIRC5-imatinib, TK1-ergotamine) showing stable binding via MD simulations.

Conclusions:

• The study proposes novel biomarker-drug pairings for prostate cancer using a unique combination of transcriptomic integration and molecular dynamics validation.
• The identified genes (BIRC5, CDCA5, CENPF, NUSAP1, TK1) show potential as PCa biomarkers.
• The repurposed drugs identified offer promising leads for future experimental and clinical validation in PCa therapy.